Blood Glucose System Maker Asks High Court To Decide Who Institutes Inter Partes Review
Mealey's (October 13, 2016, 5:43 PM EDT) -- WASHINGTON, D.C. — A manufacturer of a blood glucose monitoring system on Sept. 20 petitioned the U.S. Supreme Court to decide whether the Leahy-Smith America Invents Act (AIA) permits the Patent Trial and Appeal Board instead of the director of the U.S. Patent and Trademark Office to make inter partes review (IPR) institution decisions (LifeScan Scotland Ltd. v. Pharmatech Solutions Inc. and Michelle K. Lee, Director, U.S. Patent and Trademark Office, No. 16-377, U.S. Sup.).
(Petition for writ of certiorari available. Document #78-161017-001B.)